 | • レポートコード：MRC2312MG15433 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、103ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥481,000 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥721,500 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界の同種幹細胞移植市場規模と予測を収録しています。・世界の同種幹細胞移植市場：売上、2018年-2023年、2024年-2029年 ・世界の同種幹細胞移植市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の同種幹細胞移植市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「非改変幹細胞移植」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 同種幹細胞移植のグローバル主要企業は、Mesoblast Limited、 Gamida Cell Ltd.、 Novartis International AG、 Cellectis SA、 Magenta Therapeutics Inc.、 Fate Therapeutics Inc.、 Cynata Therapeutics Limited、 Kiadis Pharma N.V、 Takeda Pharmaceutical Company Limited、 JCR Pharmaceuticals Co., Ltd.、 Pluristem Therapeutics Inc.、 Celularity Inc.、 Lineage Cell Therapeutics Inc.、 Nohla Therapeutics Inc.、 Orchard Therapeutics Plcなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、同種幹細胞移植のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の同種幹細胞移植市場：タイプ別、2018年-2023年、2024年-2029年 世界の同種幹細胞移植市場：タイプ別市場シェア、2022年 ・非改変幹細胞移植、T細胞除去移植、臍帯血移植、ドナーリンパ球注入 世界の同種幹細胞移植市場：用途別、2018年-2023年、2024年-2029年 世界の同種幹細胞移植市場：用途別市場シェア、2022年 ・病院、外来手術センター、その他 世界の同種幹細胞移植市場：地域・国別、2018年-2023年、2024年-2029年 世界の同種幹細胞移植市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における同種幹細胞移植のグローバル売上、2018年-2023年 ・主要企業における同種幹細胞移植のグローバル売上シェア、2022年 ・主要企業における同種幹細胞移植のグローバル販売量、2018年-2023年 ・主要企業における同種幹細胞移植のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Mesoblast Limited、 Gamida Cell Ltd.、 Novartis International AG、 Cellectis SA、 Magenta Therapeutics Inc.、 Fate Therapeutics Inc.、 Cynata Therapeutics Limited、 Kiadis Pharma N.V、 Takeda Pharmaceutical Company Limited、 JCR Pharmaceuticals Co., Ltd.、 Pluristem Therapeutics Inc.、 Celularity Inc.、 Lineage Cell Therapeutics Inc.、 Nohla Therapeutics Inc.、 Orchard Therapeutics Plc ************************************************************* ・調査・分析レポートの概要 同種幹細胞移植市場の定義 市場セグメント 世界の同種幹細胞移植市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の同種幹細胞移植市場規模 世界の同種幹細胞移植市場規模：2022年 VS 2029年 世界の同種幹細胞移植市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの同種幹細胞移植の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の同種幹細胞移植製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：非改変幹細胞移植、T細胞除去移植、臍帯血移植、ドナーリンパ球注入 同種幹細胞移植のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：病院、外来手術センター、その他 同種幹細胞移植の用途別グローバル売上・予測 ・地域別市場分析 地域別同種幹細胞移植市場規模 2022年と2029年 地域別同種幹細胞移植売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Mesoblast Limited、 Gamida Cell Ltd.、 Novartis International AG、 Cellectis SA、 Magenta Therapeutics Inc.、 Fate Therapeutics Inc.、 Cynata Therapeutics Limited、 Kiadis Pharma N.V、 Takeda Pharmaceutical Company Limited、 JCR Pharmaceuticals Co., Ltd.、 Pluristem Therapeutics Inc.、 Celularity Inc.、 Lineage Cell Therapeutics Inc.、 Nohla Therapeutics Inc.、 Orchard Therapeutics Plc ... |
This research report provides a comprehensive analysis of the Allogeneic Stem Cell Transplantation market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Allogeneic Stem Cell Transplantation market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Allogeneic Stem Cell Transplantation, challenges faced by the industry, and potential opportunities for market players.
The global Allogeneic Stem Cell Transplantation market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Allogeneic Stem Cell Transplantation market presents opportunities for various stakeholders, including Hospital, Ambulatory Surgical Center. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Allogeneic Stem Cell Transplantation market. Additionally, the growing consumer demand present avenues for market expansion.
The global Allogeneic Stem Cell Transplantation market was valued at US$ 943.2 million in 2022 and is projected to reach US$ 1443.8 million by 2029, at a CAGR of 6.3% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the Allogeneic Stem Cell Transplantation market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Allogeneic Stem Cell Transplantation market.
Market Overview: The report provides a comprehensive overview of the Allogeneic Stem Cell Transplantation market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Unmodified Stem Cell Transplant, T-cell Depleted Transplant), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Allogeneic Stem Cell Transplantation market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Allogeneic Stem Cell Transplantation market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Allogeneic Stem Cell Transplantation market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Allogeneic Stem Cell Transplantation market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Allogeneic Stem Cell Transplantation market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Allogeneic Stem Cell Transplantation market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Allogeneic Stem Cell Transplantation, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Allogeneic Stem Cell Transplantation market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Allogeneic Stem Cell Transplantation market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Unmodified Stem Cell Transplant
T-cell Depleted Transplant
Cord Blood Transplant
Donor Lymphocyte Infusion
Market segment by Application
Hospital
Ambulatory Surgical Center
Others
Global Allogeneic Stem Cell Transplantation Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Mesoblast Limited
Gamida Cell Ltd.
Novartis International AG
Cellectis SA
Magenta Therapeutics Inc.
Fate Therapeutics Inc.
Cynata Therapeutics Limited
Kiadis Pharma N.V
Takeda Pharmaceutical Company Limited
JCR Pharmaceuticals Co., Ltd.
Pluristem Therapeutics Inc.
Celularity Inc.
Lineage Cell Therapeutics Inc.
Nohla Therapeutics Inc.
Orchard Therapeutics Plc
Outline of Major Chapters:
Chapter 1: Introduces the definition of Allogeneic Stem Cell Transplantation, market overview.
Chapter 2: Global Allogeneic Stem Cell Transplantation market size in revenue.
Chapter 3: Detailed analysis of Allogeneic Stem Cell Transplantation company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Allogeneic Stem Cell Transplantation in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Allogeneic Stem Cell Transplantation Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Allogeneic Stem Cell Transplantation Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Allogeneic Stem Cell Transplantation Overall Market Size
2.1 Global Allogeneic Stem Cell Transplantation Market Size: 2022 VS 2029
2.2 Global Allogeneic Stem Cell Transplantation Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Allogeneic Stem Cell Transplantation Players in Global Market
3.2 Top Global Allogeneic Stem Cell Transplantation Companies Ranked by Revenue
3.3 Global Allogeneic Stem Cell Transplantation Revenue by Companies
3.4 Top 3 and Top 5 Allogeneic Stem Cell Transplantation Companies in Global Market, by Revenue in 2022
3.5 Global Companies Allogeneic Stem Cell Transplantation Product Type
3.6 Tier 1, Tier 2 and Tier 3 Allogeneic Stem Cell Transplantation Players in Global Market
3.6.1 List of Global Tier 1 Allogeneic Stem Cell Transplantation Companies
3.6.2 List of Global Tier 2 and Tier 3 Allogeneic Stem Cell Transplantation Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Allogeneic Stem Cell Transplantation Market Size Markets, 2022 & 2029
4.1.2 Unmodified Stem Cell Transplant
4.1.3 T-cell Depleted Transplant
4.1.4 Cord Blood Transplant
4.1.5 Donor Lymphocyte Infusion
4.2 By Type – Global Allogeneic Stem Cell Transplantation Revenue & Forecasts
4.2.1 By Type – Global Allogeneic Stem Cell Transplantation Revenue, 2018-2023
4.2.2 By Type – Global Allogeneic Stem Cell Transplantation Revenue, 2024-2029
4.2.3 By Type – Global Allogeneic Stem Cell Transplantation Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Allogeneic Stem Cell Transplantation Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Ambulatory Surgical Center
5.1.4 Others
5.2 By Application – Global Allogeneic Stem Cell Transplantation Revenue & Forecasts
5.2.1 By Application – Global Allogeneic Stem Cell Transplantation Revenue, 2018-2023
5.2.2 By Application – Global Allogeneic Stem Cell Transplantation Revenue, 2024-2029
5.2.3 By Application – Global Allogeneic Stem Cell Transplantation Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Allogeneic Stem Cell Transplantation Market Size, 2022 & 2029
6.2 By Region – Global Allogeneic Stem Cell Transplantation Revenue & Forecasts
6.2.1 By Region – Global Allogeneic Stem Cell Transplantation Revenue, 2018-2023
6.2.2 By Region – Global Allogeneic Stem Cell Transplantation Revenue, 2024-2029
6.2.3 By Region – Global Allogeneic Stem Cell Transplantation Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Allogeneic Stem Cell Transplantation Revenue, 2018-2029
6.3.2 US Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.3.3 Canada Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.3.4 Mexico Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Allogeneic Stem Cell Transplantation Revenue, 2018-2029
6.4.2 Germany Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.4.3 France Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.4.4 U.K. Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.4.5 Italy Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.4.6 Russia Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.4.7 Nordic Countries Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.4.8 Benelux Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Allogeneic Stem Cell Transplantation Revenue, 2018-2029
6.5.2 China Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.5.3 Japan Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.5.4 South Korea Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.5.5 Southeast Asia Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.5.6 India Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Allogeneic Stem Cell Transplantation Revenue, 2018-2029
6.6.2 Brazil Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.6.3 Argentina Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Allogeneic Stem Cell Transplantation Revenue, 2018-2029
6.7.2 Turkey Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.7.3 Israel Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.7.4 Saudi Arabia Allogeneic Stem Cell Transplantation Market Size, 2018-2029
6.7.5 UAE Allogeneic Stem Cell Transplantation Market Size, 2018-2029
7 Allogeneic Stem Cell Transplantation Companies Profiles
7.1 Mesoblast Limited
7.1.1 Mesoblast Limited Company Summary
7.1.2 Mesoblast Limited Business Overview
7.1.3 Mesoblast Limited Allogeneic Stem Cell Transplantation Major Product Offerings
7.1.4 Mesoblast Limited Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.1.5 Mesoblast Limited Key News & Latest Developments
7.2 Gamida Cell Ltd.
7.2.1 Gamida Cell Ltd. Company Summary
7.2.2 Gamida Cell Ltd. Business Overview
7.2.3 Gamida Cell Ltd. Allogeneic Stem Cell Transplantation Major Product Offerings
7.2.4 Gamida Cell Ltd. Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.2.5 Gamida Cell Ltd. Key News & Latest Developments
7.3 Novartis International AG
7.3.1 Novartis International AG Company Summary
7.3.2 Novartis International AG Business Overview
7.3.3 Novartis International AG Allogeneic Stem Cell Transplantation Major Product Offerings
7.3.4 Novartis International AG Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.3.5 Novartis International AG Key News & Latest Developments
7.4 Cellectis SA
7.4.1 Cellectis SA Company Summary
7.4.2 Cellectis SA Business Overview
7.4.3 Cellectis SA Allogeneic Stem Cell Transplantation Major Product Offerings
7.4.4 Cellectis SA Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.4.5 Cellectis SA Key News & Latest Developments
7.5 Magenta Therapeutics Inc.
7.5.1 Magenta Therapeutics Inc. Company Summary
7.5.2 Magenta Therapeutics Inc. Business Overview
7.5.3 Magenta Therapeutics Inc. Allogeneic Stem Cell Transplantation Major Product Offerings
7.5.4 Magenta Therapeutics Inc. Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.5.5 Magenta Therapeutics Inc. Key News & Latest Developments
7.6 Fate Therapeutics Inc.
7.6.1 Fate Therapeutics Inc. Company Summary
7.6.2 Fate Therapeutics Inc. Business Overview
7.6.3 Fate Therapeutics Inc. Allogeneic Stem Cell Transplantation Major Product Offerings
7.6.4 Fate Therapeutics Inc. Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.6.5 Fate Therapeutics Inc. Key News & Latest Developments
7.7 Cynata Therapeutics Limited
7.7.1 Cynata Therapeutics Limited Company Summary
7.7.2 Cynata Therapeutics Limited Business Overview
7.7.3 Cynata Therapeutics Limited Allogeneic Stem Cell Transplantation Major Product Offerings
7.7.4 Cynata Therapeutics Limited Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.7.5 Cynata Therapeutics Limited Key News & Latest Developments
7.8 Kiadis Pharma N.V
7.8.1 Kiadis Pharma N.V Company Summary
7.8.2 Kiadis Pharma N.V Business Overview
7.8.3 Kiadis Pharma N.V Allogeneic Stem Cell Transplantation Major Product Offerings
7.8.4 Kiadis Pharma N.V Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.8.5 Kiadis Pharma N.V Key News & Latest Developments
7.9 Takeda Pharmaceutical Company Limited
7.9.1 Takeda Pharmaceutical Company Limited Company Summary
7.9.2 Takeda Pharmaceutical Company Limited Business Overview
7.9.3 Takeda Pharmaceutical Company Limited Allogeneic Stem Cell Transplantation Major Product Offerings
7.9.4 Takeda Pharmaceutical Company Limited Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.9.5 Takeda Pharmaceutical Company Limited Key News & Latest Developments
7.10 JCR Pharmaceuticals Co., Ltd.
7.10.1 JCR Pharmaceuticals Co., Ltd. Company Summary
7.10.2 JCR Pharmaceuticals Co., Ltd. Business Overview
7.10.3 JCR Pharmaceuticals Co., Ltd. Allogeneic Stem Cell Transplantation Major Product Offerings
7.10.4 JCR Pharmaceuticals Co., Ltd. Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.10.5 JCR Pharmaceuticals Co., Ltd. Key News & Latest Developments
7.11 Pluristem Therapeutics Inc.
7.11.1 Pluristem Therapeutics Inc. Company Summary
7.11.2 Pluristem Therapeutics Inc. Business Overview
7.11.3 Pluristem Therapeutics Inc. Allogeneic Stem Cell Transplantation Major Product Offerings
7.11.4 Pluristem Therapeutics Inc. Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.11.5 Pluristem Therapeutics Inc. Key News & Latest Developments
7.12 Celularity Inc.
7.12.1 Celularity Inc. Company Summary
7.12.2 Celularity Inc. Business Overview
7.12.3 Celularity Inc. Allogeneic Stem Cell Transplantation Major Product Offerings
7.12.4 Celularity Inc. Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.12.5 Celularity Inc. Key News & Latest Developments
7.13 Lineage Cell Therapeutics Inc.
7.13.1 Lineage Cell Therapeutics Inc. Company Summary
7.13.2 Lineage Cell Therapeutics Inc. Business Overview
7.13.3 Lineage Cell Therapeutics Inc. Allogeneic Stem Cell Transplantation Major Product Offerings
7.13.4 Lineage Cell Therapeutics Inc. Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.13.5 Lineage Cell Therapeutics Inc. Key News & Latest Developments
7.14 Nohla Therapeutics Inc.
7.14.1 Nohla Therapeutics Inc. Company Summary
7.14.2 Nohla Therapeutics Inc. Business Overview
7.14.3 Nohla Therapeutics Inc. Allogeneic Stem Cell Transplantation Major Product Offerings
7.14.4 Nohla Therapeutics Inc. Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.14.5 Nohla Therapeutics Inc. Key News & Latest Developments
7.15 Orchard Therapeutics Plc
7.15.1 Orchard Therapeutics Plc Company Summary
7.15.2 Orchard Therapeutics Plc Business Overview
7.15.3 Orchard Therapeutics Plc Allogeneic Stem Cell Transplantation Major Product Offerings
7.15.4 Orchard Therapeutics Plc Allogeneic Stem Cell Transplantation Revenue in Global Market (2018-2023)
7.15.5 Orchard Therapeutics Plc Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer